A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

NCT01715818 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1999

Enrollment

INDUSTRY

Sponsor class

Conditions

Cardiovascular Disease, Diabetes Mellitus Type 2

Interventions

DRUG: Placebo
DRUG: aleglitazar

Sponsor

Hoffmann-La Roche